{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:38:13Z","timestamp":1789814293781,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005320","name":"AcademyHealth","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000936","name":"Gordon and Betty Moore Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000936","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K24"],"award-info":[{"award-number":["K24"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000980","name":"Arthritis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012495","name":"Spondylitis Association of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012495","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017759","name":"Childhood Arthritis and Rheumatology Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017759","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.rdc.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T23:35:56Z","timestamp":1749512156000},"page":"469-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Challenges of New Biologic Therapies in Pediatrics"],"prefix":"10.1016","volume":"51","author":[{"given":"Anna","family":"Costello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rdc.2025.05.002_bib1","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2025.05.002_bib2","series-title":"Textbook of pediatric rheumatology","author":"Petty","year":"2020"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.002_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/art.30076","article-title":"Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis","volume":"63","author":"Ravelli","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.002_bib4","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/annrheumdis-2012-201388","article-title":"It is time to rethink juvenile idiopathic arthritis classification and nomenclature","volume":"71","author":"Martini","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.002_bib5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.002_bib6","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/acr.25296","volume":"76","author":"Shoop-Worrall","year":"2024","journal-title":"Arthritis Care Res"},{"issue":"10136","key":"10.1016\/j.rdc.2025.05.002_bib7","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.002_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/pde.15185","article-title":"Manifestation of anxiety and depression among pediatric patients with psoriasis: a review","volume":"40","author":"Strouphauer","year":"2023","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.05.002_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/pde.13772","article-title":"A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population","volume":"36","author":"Paller","year":"2019","journal-title":"Pediatr Dermatol"},{"issue":"8","key":"10.1016\/j.rdc.2025.05.002_bib10","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.002_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11758","article-title":"Characteristics that predict psoriatic arthritis by the classification criteria for psoriatic arthritis in patients with juvenile idiopathic arthritis 18 Years after disease onset","volume":"7","author":"Szentpetery","year":"2024","journal-title":"ACR Open Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2025.05.002_bib12","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1002\/art.22173","article-title":"Patients with juvenile psoriatic arthritis comprise two distinct populations","volume":"54","author":"Stoll","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.002_bib13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American College of rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.002_bib14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/acr.23870","article-title":"2019 American College of rheumatology\/arthritis foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.002_bib15","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/acr.23871","article-title":"2019 American College of rheumatology\/arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis","volume":"71","author":"Angeles-Han","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.002_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.002_bib18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.002_bib19","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bjd.19018","article-title":"Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (\u2265 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study","volume":"183","author":"Philipp","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rdc.2025.05.002_bib20","unstructured":"Institute of Medicine (US) Forum on Drug Discovery, Current challenges in developing and prescribing drugs for children, In: Addressing the barriers to pediatric drug development: workshop summary, 2008, National Academies Press (US), Washington (DC), 1-52. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK3995\/ (Accessed 10 December 2024)."},{"issue":"5","key":"10.1016\/j.rdc.2025.05.002_bib21","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/cpt.1886","article-title":"Combined pediatric and adult trials submitted to the US Food and drug Administration 2012\u20132018","volume":"108","author":"Tanaudommongkon","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"10315","key":"10.1016\/j.rdc.2025.05.002_bib22","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2025.05.002_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.884727","article-title":"New insights on juvenile psoriatic arthritis","volume":"10","author":"Brunello","year":"2022","journal-title":"Front Pediatr"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.002_bib24","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study","volume":"73","author":"Horneff","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.002_bib25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40272-022-00533-y","volume":"24","author":"Leu","year":"2022","journal-title":"Paediatr Drugs"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.002_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/ard-2022-222849","article-title":"Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial","volume":"82","author":"Brunner","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9894","key":"10.1016\/j.rdc.2025.05.002_bib28","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.002_bib29","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2025.05.002_bib31","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40466","article-title":"Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis","volume":"70","author":"Brunner","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2025.05.002_bib33","article-title":"Pharmacokinetics, efficacy, and safety of upadacitinib in pediatric patients with polyarticular-course juvenile idiopathic arthritis: an interim analysis of an open-label, phase 1 trial","author":"Brunner","year":"2024","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2025.05.002_bib40","article-title":"25 Years of biologics for the treatment of pediatric rheumatic diseases - advances in prognosis and ongoing challenges","author":"Shishov","year":"2024","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.002_bib42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamapediatrics.2018.3416","article-title":"Completion rate and reporting of mandatory pediatric postmarketing studies under the US pediatric research equity act","volume":"173","author":"Hwang","year":"2019","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.rdc.2025.05.002_bib45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13023-024-03097-x","article-title":"Analysis of the first ten years of FDA\u2019s rare pediatric disease priority review voucher program: designations, diseases, and drug development","volume":"19","author":"Mease","year":"2024","journal-title":"Orphanet J Rare Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:59:16Z","timestamp":1778543956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X25000250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0889857X25000250"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.05.002","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Challenges of New Biologic Therapies in Pediatrics","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}